1	FAR AWAY FROM HERD IMMUNITY TO SARS-CoV-2: results from a				
2	survey in healthy blood donors in South Eastern Italy				
3					
4	Josè Ramòn Fiore1, Michele Centra2, Armando De Carlo3*, Tommaso Granato2, Annamaria				
5	Rosa3*, Michelina Sarno2, Lucia De Feo2, Mariantonietta Di Stefano1, Maria L. D'Errico1,				
6	Sergio Lo Caputo1, Rosella De Nittis4, Fabio Arena4, Gaetano Corso5, Maurizio				
7	Margaglione6 Teresa Antonia Santantonio1				
8					
9	1) Department of Clinical and Experimental Medicine, Section of Infectious Diseases, University of				
10	Foggia, School of Medicine, Foggia, Italy				
11	2) Transfusion Medicine Center, Ospedali Riuniti University Hospital, Foggia, Italy				
12	3) Laboratory analysis, Ospedali Riuniti University Hospital, Foggia, Italy				
13	4) Department of Clinical and Experimental Medicine, Section of Microbiology, University of Foggia,				
14	School of Medicine, Foggia, Italy				
15	5) Department of Clinical and Experimental Medicine, Section of Clinical Biochemistry, University of				
16	Foggia, School of Medicine, Foggia, Italy				
17	6) Department of Clinical and Experimental Medicine, Section of Genetics, University of Foggia,				
18	School of Medicine, Foggia, Italy				
19					
20	Corresponding Author				
21	Jose Ramon Fiore MD, PhD				
22	Department of Clinical and Experimental Medicine				
23	Section of Infectious Diseases, University of Foggia				
24	Ospedali Riuniti University Hospital				
25	Via Luigi Pinto 1 71100 Foggia (Italy)				
26	Email jose.fiore@unifg.it				

- 27 ABSTRACT
- 28

Here we present results from a survey on anti-SARS-CoV-2 seroprevalence in healthy blood donors
from a low incidence COVID-19 area (Apulia region, South Eastern Italy).

Among 904 subjects tested, only in 9 cases (0.99%) antibodies against SARS-CoV-2 were demonstrated. All the 9 seropositive patients were negative for the research of viral RNA by RT-PCR in nasopharyngeal swab.

These data, along with those recently reported from other countries, clearly show that we are very far from herd immunity and that the containment measures are at the moment the only realistic instrument we have to slow the spread of the pandemic.

37

39 INTRODUCTION

40

Herd immunity is a concept in epidemiology that describes how people can collectively stave off infections if some percentage of the population has immunity to it. When most of a population is immune to an infectious disease, this provides indirect protection, or herd protection, to those who are not immune (1)

There are two ways to achieve herd immunity: a large proportion of the population either gets infected or gets a protective vaccine. Based on early estimates of SARS-CoV-2 infectiousness, it should be likely needed at least 60-70% of the population to be immune to have herd protection (2). However, more recently mathematical models suggest that lower thresholds could be enough to place populations over the herd immunity threshold once as few as 43% (3) or even10-20% of its individuals are immune. (4)

51 It is therefore important and urgent to evaluate the extent of circulation (and thus of immunity to)

52 Of SARS-CoV-2 in the general populations of affected countries because this information should 53 guide the extent of reduction or increasing of preventive measures such as social distancing etc.

Italy registered the first imported cases of infection in January 31 2020 and after one week the first local case. After that, a dramatic burden of infections was diagnosed: 235.278 cases (with 33.964 deaths) as for **June 8** 2020, with main clusters in Northern Italy. As a whole, 390 infections/100.000 inhabitants. In Foggia (Apulia region, South Eastern Italy) the first case was observed in March the 1st and as for **June 8**, 1162 cases were diagnosed with an incidence of 187 cases/100.000 inhabitants (5)).

Although the total number of diagnosed infections is moderate, we miss clear information regarding
the number of individuals in the general population that became immune, possibly acquiring the
virus with no or mild symptoms.

- 63 Studies on blood donor cohorts are useful to evaluate the prevalence, incidence and natural course
 64 of infectious diseases in the general population and may thus help to assess both the viral
 65 circulation and the evolution of the COVID-19 outbreak.
- 66 We therefore studied a group of healthy blood donors from Foggia province for the presence of IgM
- 67 and IgG to antibodies to SARS-CoV-2 to examine the circulation of the virus in the general
- 68 population three months after the local start of the epidemic.
- 69

70 SUBJECTS, MATERIAL AND METHODS

71

72 SUBJECTS

73 The main study cohort was composed of blood donors, who were apparently healthy subjects, aged 74 18-65 years. Exclusion criteria were active infection or medical conditions, recent surgical 75 procedures, stay in endemic areas, reported risk factors for parenterally acquired infections, chronic 76 degenerative conditions, diagnosis of cancer or high risk of cardiovascular events. All donors 77 underwent clinical examination, medical history evaluation and biochemical testing. All subjects 78 should had been free of recent symptoms possibly related to COVID-19, nor had close contact with 79 confirmed cases, symptoms free during the preceding 14 days, nor had contacts with suspected 80 cases.

Each blood donor signed written informed consents allowing for testing for communicable diseases,
storing anonymized data and biological materials for diagnostic/research purposes, and use of their
anonymous data for clinical research.

A total of 904 blood donors, referring to the Transfusional Center at the "Ospedali Riuniti" University Hospital (Foggia, Italy) were included in the study and subjected to the search for anti-SARS-CoV-2 antibodies, in the period May1-31 2020. In the case of positivity, subjects were recalled and RT-PCR for detection SARS-CoV-2 from nasopharyngeal swabs was performed.

89 **METHODS**

90

91 Detection of anti SARS Cov 2 antibodies

92 Anti-SARS-CoV-2 IgG and IgM were analyzed by using a chemiluminescent analytical assay 93 (CLIA) commercially available kit (New Industries Biomedical Engineering Co., Ltd [Snibe], 94 Shenzhen, China) performed according to the manufacturers instructions. Reagent wells were 95 coated with recombinant structural protein CoV-S (spike) and e CoV-N (nucleocapside) of SARS-96 CoV-2 for both IgM and IgG assay. For IgM assay, the microspheres were coated with a 97 monoclonal antibody to capture human IgM followed by the addition of recombinant antigen from 98 virus 2019-nCoV marked with amino-butyl-ethyl-isoluminol (ABEI). The samples, serum or 99 plasma, were diluted by instrument. The relative light units (RLU) detected is proportional to the 100 concentration of IgG/M in sample. An RLU-ratio of the measurement of each sample to the 101 supplied calibrator was calculated. According to manufacturer instructions for the IgG assay 102 arbitrary units of <1 was considered negative, 1.0 to 1.1 borderline and >1.1 positive; for IgM, an 103 AU/mL <0.9 was considered negative, 0.9 to 1.0 borderline and > 1.0 positive.

104 Manufacturers claimed that the calculated clinical sensitivities of IgM and IgG were 78.65% and

105 91.21%, respectively, while specificities of IgM and IgG were 97.50% and 97.3%, respectively.

106

107 RT-PCR for detection SARS-CoV-2 from nasopharyngeal swabs

108 Viral RNA was extracted within 2 hours from sample collection using the STARMag 96 X 4 109 Universal Cartridge kit with the Microlab NIMBUS IVD instrument according to the 110 manufacturer's instructions (Seegene Inc. Seoul, Korea). Amplification and detection of target 111 genes (N, E and RdRP) was performed using the commercially available kit AllplexTM 2019-nCoV 112 Assay (Seegene Inc. Seoul, Korea) with the CFX96TM instrument (Bio-Rad, Hercules, CA). 113 Results interpretation was performed with the Seegene Viewer software. 115 **RESULTS**

116

- 117 A total of 904 subjects were enrolled in this study (666 males and 239 females) ranging from 18 to
- 118 65 years (Table 1). Among them, 9 tested positive for antibodies to SARS-CoV-2: in 8 cases only
- 119 IgG antibodies were found while in 1 case both IgG and IgM were detected, with a percentage of
- 120 positivity in the blood donor population of 0.99 %.
- 121 No statistical differences were observed in the rate of antibody detection according to the sex and122 the age.
- 123 None of these subjects had clinical signs or symptoms and laboratory parameters alterations; all of
- 124 them tested negative for RT-PCR research of SARS-CoV-2 RNA in two nasopharyngeal swabs
- 125 performed on two consecutive days.

126

127

129 **DISCUSSION**

130

Herd immunity is the resistance to the spread of a contagious disease that results if a sufficientproportion of a population is immune due to natural infection or mass vaccination.

133 Because an effective COVID-19 vaccine is not yet available, herd immunity can be established if a 134 large proportion of immune persons exist in a population to confer indirect protection from 135 infection to susceptible individuals. The breadth of the barrier required to achieve herd immunity 136 depends in large part on viral spread and infectivity. In the nomenclature of epidemiology, the basic 137 reproduction number or R0 and the classical formula for calculating a herd immunity threshold is 138 1-1/R0. The higher the R0, the higher the threshold required for achieving herd immunity. Other 139 important factors in calculating herd immunity thresholds include the number of social interactions 140 and their durations, innate differences in individual immune responses, and divergent exposures to 141 the infectious microbe (1)

142 People who recover from a COVID-19 coronavirus infection, at least for some time, develop143 immunity to the virus (6).

The disease-induced herd immunity threshold for SARS-CoV-2, according to various epidemiologists, is believed to be around 60 to 70 percent (2) More recently, some researchers have reported lower thresholds: from 43% to just 10 to 20% of the population (3, 4), suggesting that we could reach herd immunity thresholds by natural infections in the setting of COVID-19 pandemic.

Recently, data from Spain, France and Italy (7-9) countries that adopted strict lockdown measures indicate a very low seroprevalence in the general population (4.4%, 5% and 7.1%, respectively). Noteworthy, even in Sweden, a country that decided for a herd immunity strategy, with very light restrictions on daily life, antibodies to SARS-CoV-2 were detectable in only 7.5% of the general population in Stockholm (10).

In other geographical regions, serosurveys in healthy individuals demonstrated a very low rate of
positivity for SARS-CoV-2 (11-15).

155 In our study, we confirm a low rate of antibodies against SARS-CoV-2 on a group of blood donors

156 from a geographical region with a moderate incidence (187 cases/100.000 inhabitants vs the

- 157 national data of 390 infections/100.000 inhabitants).
- 158 A limitation of our study is that the enrolled population (18-65 years old) is representative of only a
- 159 part of the general population, since in Italy 22% of the individuals is aged >65 years (16)

160 However, presented data are relevant in that they refer to the more acting/interacting group of the

161 population, also important from a productive point of view.

162 Certainly, we are far away from herd immunity and even from the more optimistic projections of

163 threshold (10 to 20% of the population) to adopt more relaxed strategies.

In conclusion, strengthening herd immunity to control the COVID-19 epidemic is not a viable option as large numbers of people are expected to become infected and many may die from COVID-19. Preventive measures, including physical distancing, remain essential to contain the spread of infection until herd immunity can be safely acquired with the vaccine. Health authorities should take in account these considerations when facing the public health measures to be adopted throughout the COVID-19 transition phases.

175

177	1)	Metcalf C.J.E, Ferrari M., Graham A.L., Grenfell B.T. Understanding Herd
178		Immunity. Trends Immunol. 2015;36(12):753-755.
179		
180	2)	Randolph H.E., Barreiro L.B. Herd Immunity: Understanding COVID-19. Immunity.
181		2020;52(5):737 🗆 741.
182		
183	3)	Britton T., Trapman P., Ball F.G. The disease-induced herd immunity level for Covid-19 is
184		substantially lower than the classical herd immunity level.
185		medRxiv 2020.05.06.20093336; doi: https://doi.org/10.1101/2020.05.06.20093336
186		
187	4)	Gabriela M., Gomes M., Corder R. M., King, J. G., Langwig K. E., Souto-Maior, C. et al,
188		Individual variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity
189		threshold. medRxiv 2020.04.27.20081893. https://doi.org/10.1101/2020.04.27.20081893
190		
191	5)	http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioNotizieNuovoCoronavirus.jsp?li
192		ngua=italiano&menu=notizie&p=dalministero&id=4870
193		
194	6)	Braun J., Loyal L., Frentsch M., Wendisch D., Georg P., Kurth F. et al. Presence of SARS-
195		CoV-2 reactive T cells in COVID-19 patients and healthy donors.
196		MedRxiv 2020.04.17.20061440; doi: https://doi.org/10.1101/2020.04.17.20061440
197		
198	7)	Ministerio de Sanidad, Consumo y Bienestar Social Estudio Ene COVID 19: Primera ronda
199		estudio nacional de sero-epidemiologia de la infeccion por SARS-COV-2 en Espana.
200		Informe preliminar 13 de Mayo de 2020
201		https://www.mscbs.gob.es/gabinetePrensa/notaPrensa/pdf/ENE-C140520115618104.pdf
202		

203	8) Salje H., Tran Kiem C., Lefrancq N., Courtejoie N., Bosetti P., Paireau J. et al. Estimating			
204	the burden of SARS-CoV-2 in France [published online ahead of print, 2020 May			
205	13]. Science. 2020;eabc3517. doi:10.1126/science.abc3517			
206				
207	9) Valenti L., Bergna A., Pelusi S., Facciotti F., Lai A., Tarkowski M. et al. SARS-CoV-2			
208	seroprevalence trends in healthy blood donors during the COVID-19 Milan outbreak.			
209	medRxiv 2020.05.11.20098442 doi: http://org/10.1101/2020.05.11.20098442			
210				
211	10) https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2020/maj/forsta-			
212	resultaten-fran-pagaende-undersokning-av-antikroppar-for-covid-19			
213	virus/?fbclid=IwAR0BK_fKQ2l9q4upW4LbMH4celkIaTXIyrvwvOW1RbaoxkJ1DKdEGP			
214	Txx6w			
215				
216	11) Sughayer M.A., Mansour A., Al Nuirat A., Souan L., Ghanem M., Siag M. Covid-19			
217	Seroprevalence rate in healthy blood donors from a community under strict lockdown			
218	measures			
219	medRxiv 2020.06.06.20123919; doi: https://doi.org/10.1101/2020.06.06.20123919			
220				
221	12) Kai Wang-to K., Chi-Chung Cheng V., Cai J. P., Chan K. H., Chen L. L., Wong L. H. at			
222	all. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei			
223	province, China: a multicohort study. Lancet microbes, June 2020 DOI: 10.1016/S2666-			
224	5247(20)30053-7			
225				
226	13) Filho L.A., Landmann Szwarcwald C., de Oliveira Garcia Mateos S,, Monteiro Ponce de			
227	Leon A., de Andrade Medronho R. , Gonçalves Veloso V et al., Seroprevalence of IgG and			

228	IgM anti-SARS-CoV-2 among voluntary blood donors in Rio de Janeiro, Brazil Scielo
229	Electronic Library Online preprint, doi: https://doi.org/10.1590/SciELOPreprints.404
230	
231	14) Sood N., Simon P., Ebner P., Eichner D., Reynolds J., Bendavid E. et al. Seroprevalence of
232	SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on
233	April 10-11, 2020 [published online ahead of print, 2020 May 18]. JAMA. 2020;e208279.
234	doi:10.1001/jama.2020.8279
235	
236	15) Ng D., Goldgof G., Shy B., Andrew L., Balcerek J., Bapat S. P. et al. SARS-CoV-2
237	seroprevalence and neutralizing activity in donor and patient blood from the San Francisco
238	Bay Area. Preprint. medRxiv. 2020;2020.05.19.20107482. Published 2020 May 25.
239	doi:10.1101/2020.05.19.20107482
240	16) https://www.tuttitalia.it/statistiche/indici-demografici-struttura-
241	popolazione/#:~:text=Struttura%20della%20popolazione%20dal%202002,anziani%2065%2
242	0anni%20ed%20oltre.
242	
243	
244	
245	
246	
247	
248	
249 250	
250 251	
252 252	
253 254	
254 255	
255 256	
250 257	
257 258	
258 259	
2 <i>39</i> 260	
261	
262	

264 TABLE 1:

Detection of antibodies to SARS Cov 2 in 904 healthy blood donors according to sex and age

	n°	Positive n $^{\circ}$	%
Total	904	9	0.99
Males	665	5	0.75
Females	239	4	1.6
Ages (range)	n°	n°	%
Group I (18 – 25)	112	1	0.89
Group II (26 – 35)	195	4	2.0
Group III (36 – 45)	202	1	0.49
Group IV (46 – 55)	246	0	0
Group IV (56–65)	149	3	2.0